Neurocrine (NBIX) Shares Plunge as Data on NBI-98854 Fails to Hit Primary Endpoint

March 26, 2012 4:08 PM EDT
Neurocrine Biosciences (Nasdaq: NBIX) shares have fallen more than 11 percent after data from a Phase II study of VMAT2 inhibitor NBI-98854 for tardive dyskinesia did not meet the primary endpoint.

The stock last traded at $7.88. Shares closed at $8.99.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Momentum Movers

Add Your Comment